Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Hay

Showing results (401-410 of 423) with videos related to

Pageof 43
Sort By:
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Blood|June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
American Journal of Hematology|November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemiaRoland B Walter, Laura C Michaelis, Megan Othus, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 16, 2018
Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluationE M Harding-Esch, S S Fuller, S-L C Chow, et al.
BMJ Open|October 22, 2025
Emergency department-initiated palliative care screening among older adults: a systematic review and meta-analysis protocolDimitri E Lin, Satheesh Gunaga, Fabrice I Mowbray, et al.
Vaccine|June 29, 2024
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignanciesSita Bhella, Allison M Wilkin, Katrina Hueniken, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2013
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphomaA E Hay, B Klimm, B E Chen, et al.
British Journal of Haematology|October 10, 2025
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignanciesAbi Vijenthira, Sita Bhella, Katrina Hueniken, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2021
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic LeukemiaMatthew C Cheung, Nicole Mittmann, Carolyn Owen, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Pageof 43

Showing results (401-410 of 423) with videos related to

Sort By:
Pageof 43
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Blood|June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
American Journal of Hematology|November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemiaRoland B Walter, Laura C Michaelis, Megan Othus, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 16, 2018
Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluationE M Harding-Esch, S S Fuller, S-L C Chow, et al.
BMJ Open|October 22, 2025
Emergency department-initiated palliative care screening among older adults: a systematic review and meta-analysis protocolDimitri E Lin, Satheesh Gunaga, Fabrice I Mowbray, et al.
Vaccine|June 29, 2024
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignanciesSita Bhella, Allison M Wilkin, Katrina Hueniken, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2013
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphomaA E Hay, B Klimm, B E Chen, et al.
British Journal of Haematology|October 10, 2025
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignanciesAbi Vijenthira, Sita Bhella, Katrina Hueniken, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2021
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic LeukemiaMatthew C Cheung, Nicole Mittmann, Carolyn Owen, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Pageof 43